Lilly posts Phase 2b retatrutide renal results; registers tersolisib kidney PK studyNov 13Weekly roundup, 10 itemsabemaciclibanastrozole
Lilly posts galunisertib PFS results in prostate cancer; registers new bimagrumab HFpEF trialNov 6Weekly roundup, 7 itemsbimagrumabEli LillyUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Arrowhead's ARO-INHBE obesity trial remains active, not recruiting, with 190 enrolledOct 30Trial updateARO-INHBEArrowhead Pharmaceuticals
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphomaOct 30Weekly roundup, 11 itemsAstellas Pharmaatirmociclib
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trialsOct 22Weekly roundup, 11 itemscetuximabdulaglutide
Roche adds Phase III trials in flu prophylaxis and diabetes, plus pediatric SMA study updateOct 22Weekly roundup, 6 itemsbaloxavir marboxilChugai PharmaceuticalUpdated
Novo Nordisk registers two zenagamtide switch studies; IMPLEMENT HF recruitment continuesOct 16Weekly roundup, 3 itemsNovo Nordisk A/SsemaglutideUpdated
Pfizer wins two FDA labeling supplements; obesity trial roster unchangedOct 15Weekly roundup, 8 itemsberobenatidemethotrexate
Novo Nordisk registers Phase 3 cardiovascular outcomes trial for zenagamtide, acronym AMBIENCEOct 9Weekly roundup, 2 itemsNovo Nordisk A/Stirzepatide
Boehringer Ingelheim registers five new trials, spanning oncology, obesity, and ILD screeningOct 2Weekly roundup, 7 itemsBoehringer IngelheimempagliflozinUpdated
Lilly posts Phase 3 orforglipron results; registers new MDD trial and five other updatesOct 2Weekly roundup, 10 itemsbaricitinibbrenipatideUpdated
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post resultsSep 30Weekly roundup, 8 itemsatirmociclibberobenatideUpdated
Lilly's orforglipron posts Phase 3 diabetes results; six new trials registeredSep 18Weekly roundup, 7 itemsEli Lillyorforglipron
Lilly posts Phase 3 orforglipron results; two more programs report terminated-trial dataSep 4Weekly roundup, 7 itemsEli Lillylasmiditan
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225
FDA approves two efficacy supplements for Eli Lilly's MounjaroAug 27Regulatory decisionEli Lillytirzepatide
FDA approves efficacy supplement for Lilly's Zepbound (tirzepatide)Aug 26Regulatory decisionEli Lillytirzepatide
Lilly posts orforglipron Phase 3 results; adds new early-phase studiesAug 14Weekly roundup, 6 itemsbaricitinibbrenipatide
Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growthAug 5Quarterly updateEli Lillytirzepatide
Lilly-linked tirzepatide alopecia trial joins mazisotine results, eloralintide recruitingJul 31Weekly roundup, 3 itemsEli Lillyeloralintide
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib